Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

480 results about "Pulmonary disorders" patented technology

Pulmonary diseases, otherwise known as lung diseases, are the third biggest cause of death in America. There are several different types of pulmonary diseases that vary in severity. According to Medline Plus, a few of the main types of pulmonary diseases include emphysema, asthma, pneumonia, tuberculosis and lung cancer.

Lung CT image segmentation method based on Transform and U-Net

The invention discloses a lung CT image segmentation method based on Transform and U-Net, and the method comprises the steps: firstly obtaining a pulmonary nodule CT scanning image, carrying out the preprocessing, then constructing a segmentation model MCSTU-Net, enabling the model to extract abundant features through the fusion of a convolutional neural network and a Swin Transform module, and enabling the segmentation model to obtain a segmentation model MCSTU-Net. Enhancing and fusing feature information from different levels through a multiple attention fusion module; dividing the data set into a training set, a test set and a verification set, training and verifying the segmentation model, and finally performing focus segmentation on the pulmonary nodule CT scanning image by using the trained and verified model. According to the model and the method constructed by the invention, lesion tissues in the lung CT image can be segmented more accurately, the effectiveness of each module is verified through an ablation experiment, and doctors are assisted to diagnose and treat lung diseases.
Owner:HANGZHOU NORMAL UNIVERSITY

Chemical ablation and method of treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Owner:NEUROTRONIC INC

Substituted pyrazolo piperidine carboxylic acids

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
Owner:BAYER AG

Kit for detecting metabolites in exhaled air condensate for lung disease detection

The invention discloses a kit for detecting metabolites in exhaled air condensate for lung disease detection, and belongs to the technical field of detection kits.The kit is characterized in that a box body is arranged at the position of an external detection mechanism, a plurality of test tubes correspond to a plurality of detection stations under the detection mechanism respectively, and a micro motor works to drive a driving disc to rotate; the driving disc drives the shifting rod to rotate, so that the shifting rod can rotate outside the bulges on the outer wall of the rotating disc, and a cavity is formed between every two adjacent bulges, so that the shifting rod can push the rotating disc to rotate through the cavities in the rotating process, and the rotating disc can rotate around the center of the bearing seat; the rotating disc drives the plurality of test tubes to synchronously rotate through the erecting assembly, so that the test tubes can be pushed to the next detection station after the current detection process is completed, and the driving lever can push the rotating disc to intermittently rotate along with the continuous rotation of the driving lever, so that the positions of the plurality of test tubes are synchronously adjusted; the purpose of continuously, efficiently and stably detecting the test tubes in the box body is effectively achieved.
Owner:HUAZHONG UNIV OF SCI & TECH

Methods, apparatuses, and systems for the treatment of pulmonary disorders

ActiveUS20250064510A1ElectrotherapySurgical instruments for heatingDiseaseAcute bronchitis
Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.
Owner:GALVANIZE THERAPEUTICS INC

Carotenoid compositions and uses thereof

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.
Owner:L E A F HLDG GRP

Lung disease multi-subtype classification method, system and equipment based on chest image

ActiveCN119206380AImage enhancementImage analysisChest imagingDisease
The invention discloses a lung disease multi-subtype classification method, system and device based on chest images, and belongs to classification of lung diseases in the technical field of artificial intelligence medicine. The method aims at solving the technical problem that in the prior art, due to the fact that a loss function cannot enable a model to pay attention to main pathology types and all pathology types in data at the same time, the multi-subtype classification accuracy of the model is low, the multi-subtype classification model is constructed, and three different losses are creatively synthesized during model training, so that the multi-subtype classification accuracy of the model is improved. The # imgabs0 # is used for enabling the model to predict all existing pathological types, the # imgabs1 # is used for enabling the model to mainly learn to predict the main pathological types, and the # imgabs2 # is used for enabling the model to restrain prototype vectors of various types to have distinction degrees, so that the model can better capture correlation among different subtypes while learning image representation of main pathological subtypes, and the model can be used for predicting the main pathological types. The generalization ability of the model is improved, the robustness of model training is improved, the overfitting problem of the model is relieved, and the accuracy of the model for multi-subtype classification is improved.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Application of phenyllactic acid or composition containing phenyllactic acid in preparation of medicine for relieving lung diseases

The invention discloses an application of phenyllactic acid or a composition containing phenyllactic acid in preparation of medicines for relieving lung diseases, and in the application, the lung diseases are preferably pulmonary fibrosis or acute lung injury. In an acute lung injury research model, phenyllactic acid can effectively intervene in the inflammatory factor cascade reaction and oxidative stress injury process, and acute lung injury symptoms caused by the factors are remarkably improved. Compared with the traditional treatment means, the experiment proves that the phenyllactic acid or the composition containing the phenyllactic acid can obviously relieve the symptoms of acute lung injury (ALI) of mice induced by lipopolysaccharide (LPS) and pulmonary fibrosis (PF) of mice induced by bleomycin, the pathological change of the lung is effectively improved, and the lung function is recovered.
Owner:THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV

Bifunctional protein targeting PD-1 and TGF [beta] and application of bifunctional protein in treatment of cancer in combination with radiotherapy

The invention relates to a bifunctional protein targeting PD-1 and TGF [beta] and application of the bifunctional protein in cancer treatment by combining radiotherapy. Specifically, the present invention relates to the use of a bifunctional protein targeting PD-1 and TGF [beta] in the preparation of a medicament for treating an individual suffering from cancer, the bifunctional protein targeting PD-1 and TGF [beta] comprising: (1) an anti-PD-1 antibody or an antigen binding fragment thereof; (2) an immunoglobulin Fc structural domain; and (3) a TGF-beta R II extracellular domain. The invention further relates to application of the PD-1 and TGF beta targeting bifunctional protein in preparation of drugs for treating or preventing lung diseases or symptoms, especially radiation-induced lung injury, caused by radiotherapy of individuals.
Owner:SHANGHAI JUNSHI BIOSCIENCES CO LTD +1

Method of quantifying lung disease

A method of using computed tomographic (CT) image data to provide a quantitative assessment of various classes of lung disease, including for example, interstitial lung abnormalities associated with interstitial lung disease (ILD) represented as a mass contribution, or as a percentage contribution by mass. Mass fractions of emphysema due to COPD are also addressed along with the special case of addressing air trapping mass fraction due to ILA / ILD, asthma, COPD, BOS.
Owner:VIDA DIAGNOSTICS

Nano preparation for delivering antibiotics based on plant extracts and application thereof

The invention relates to a nano preparation for delivering antibiotics based on plant extracts and application of the nano preparation, and belongs to the technical field of nano preparations. In order to solve the problems of low bioavailability and low action efficiency of oral administration or intravenous injection of antibiotics in the lung disease treatment process, the invention provides a nano preparation for delivering antibiotics based on plant extracts. The mass volume ratio of the antibiotics to the plant extract in the nano preparation is (1-10) mg: (20-100) mu L. The nano preparation disclosed by the invention can obviously inhibit the migration of fibroblasts, has an obvious bacteriostatic effect and can reduce the density of microorganisms in lungs; positive charges carried by the material are combined with negative charges on the surface of a bacterial cell membrane, transmembrane substance transfer on the bacterial cell membrane is affected, bacterial metabolism and reproduction are affected, adjustment of pulmonary symbiotic bacteria is better achieved, and the pulmonary fibrosis progress can be relieved. The nano preparation has the advantages of small toxic and side effects, good patient compliance, high encapsulation efficiency and the like.
Owner:HARBIN MEDICAL UNIVERSITY

Methods, apparatuses, and systems for the treatment of pulmonary disorders

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.
Owner:GALVANIZE THERAPEUTICS INC

Substituted pyrazolo piperidine carboxylic acids

ActiveUS12595247B2Organic active ingredientsNervous disorderDiabetic kidneyCardiopulmonary disease
The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
Owner:BAYER AG

Lactobacillus reuteri and application of lactobacillus reuteri in preparation of products for relieving lung diseases

The invention discloses lactobacillus reuteri and application thereof in preparation of products for relieving lung diseases, and the lactobacillus reuteri MLR1103 has the preservation number of CGMCC No.31162. Experiments prove that the lactobacillus reuteri or bacterial powder containing the lactobacillus reuteri has the characteristics of tolerance to gastric acid, intestinal juice and cholate, and can be applied to preparation of products for relieving lung diseases. Acute lung injury caused by mouse LPS, lung injury caused by PM2.5, pulmonary fibrosis, asthma, pneumoconiosis and cough symptoms can be remarkably relieved, lung pathological changes are relieved, and lung functions are recovered.
Owner:DALIAN WANRUIKANG BIOTECHNOLOGY CO LTD

Biomarkers for the treatment of interstitial lung disease

The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2 / 3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.
Owner:REIN THERAPEUTICS INC

Dosage forms of active substances used against viral diseases in dry powder inhaler device for symptoms caused by covid-19 and other viral lung diseases

The present invention relates to a pharmaceutical composition in inhalable pre-metered dry powder form that comprises at least one excipient (for example carrier) and at least one active substance used against viral diseases to locally administer it to the lungs for use in the treatment of symptoms of viral lung diseases including COVID-19 caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) by means of dry powder inhaler through inhalation. The present invention also relates to methods for preparation of said pharmaceutical composition and the use of these active substances in symptoms caused by COVID-19. similar viral lung diseases, influenza.
Owner:PULMOCURES ILAC EGITIM DANISMANLIK AS

Application of polypeptide Nod-T3 in preparation of medicine for treating lung diseases

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.
Owner:QINGPU BRANCH OF ZHONGSHAN HOSPITAL AFFILIATED TO FUDAN UNIV (SHANGHAI QINGPU DISTRICT CENT HOSPITAL)

Systems and methods for sympathetic cardiopulmonary neuromodulation

PendingUS20250339496A1Organic active ingredientsPeptide/protein ingredientsDiseaseSympathetic innervation
Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4 / 5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.
Owner:TULAVI THERAPEUTICS INC

Naphthalene and quinoline analogues as RXFP1 agonists

The present disclosure relates to compounds of formula (I) that are RXFP1 receptor agonists, compositions comprising the same, and methods of use thereof (e.g., for the treatment of heart failure, fibrosis, and related diseases, such as lung disease (e.g., idiopathic pulmonary fibrosis), renal disease (e.g., chronic kidney disease), or liver disease (e.g., nonalcoholic steatohepatitis and portal hypertension)). TIFF2024546944000073.tif59153
Owner:BRISTOL MYERS SQUIBB CO

Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).
Owner:ARENA PHARMACEUTICALS INC

In-vitro cell model for simulating particulate matter induced lung disease occurrence and application of in-vitro cell model

The invention relates to an in-vitro cell model for simulating particulate matter induced lung disease occurrence and application. According to the cell culture device, different small chambers are formed, cells between adjacent small chambers cannot be in contact, but cell factors generated by the cells can penetrate through the small chambers along with flowing of a culture medium to affect the cells, and then interaction between the cells in a body is reduced; meanwhile, the segmentation assembly is removed before the particulate matter is added, but the cells are still reserved in the small chamber, and therefore the in-vivo interaction of the particulate matter and the cells can be simulated more truly. In addition, gel does not need to be used as a support, and the real effect of particulate matter and cells in the body can be better simulated only through installation and disassembly of the segmentation assembly. Therefore, the in-vitro cell model disclosed by the invention can really simulate the interaction between in-vivo cells and accurately predict the influence of the particulate matters on the cells, and the preparation method is simple and effective and provides a new thought for the establishment of the in-vitro cell model.
Owner:SUZHOU UNIV

Multi-element machine learning model-based cross-species lung disease feature gene screening method and system, electronic system and storage device

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.
Owner:RES CENT FOR ECO ENVIRONMENTAL SCI THE CHINESE ACAD OF SCI

Composition for preventing or treating lung diseases containing CD47-overexpressing mesenchymal stem cells

Proposed is a composition for preventing or treating lung diseases. The composition may contain CD47-overexpressing mesenchymal stem cells as an active ingredient. CD47-overexpressing mesenchymal stem cells, even when not autologous, show a high survival rate in vivo and the ability to migrate to lung tissue, reduce the inflammatory response in lung tissue, and exhibit a fibrosis-inhibiting effect. CD47-overexpressing mesenchymal stem cells can be widely used for the prevention or treatment of various lung diseases related to inflammation or fibrosis of the lungs.
Owner:MEDIPOST

Spray administration device and system for lung diseases

The invention relates to the technical field of medical equipment, in particular to a spray dosing device and system for lung diseases, comprising a shell in which a medicine storage bin for storing liquid medicine and an atomizing component for atomizing and spraying the liquid medicine are mounted, the atomization assembly is communicated with the medicine storage bin, the respiration triggering assembly is installed at the end, away from the medicine storage bin, of the atomization assembly, the airflow adjusting assembly is installed in the atomization assembly, and the atomization assembly is communicated with the medicine storage bin. The airflow adjusting assembly is in signal connection with a controller, and the controller is in signal connection with the atomization assembly and the respiration triggering assembly. The system is used for achieving accurate and intelligent spray administration according to the breathing state of a patient, the deposition efficiency of medicine in the lung is improved, the treatment effect is optimized, and formulation of a personalized treatment scheme is achieved.
Owner:TIANJIN UNIV

Sodium pyruvate sustained-release nano system based on targeted modification as well as preparation method and application thereof

The invention belongs to the field of biological medicine, and particularly relates to a sodium pyruvate slow-release nano system based on targeted modification and a preparation method and application thereof. The preparation method of the slow-release nano system comprises the following steps: a, preparing modified silk fibroin; and b, under a homogenizing condition, adding a mixed aqueous solution of sodium phytate and sodium pyruvate into the modified silk fibroin aqueous solution, obtaining a mixed solution after homogenizing is finished, stirring the mixed solution for reaction, centrifuging the reaction solution after the reaction is finished, collecting precipitates, washing and dialyzing to obtain the sodium pyruvate slow-release nano system based on targeted modification. The sustained-release nano-system has good biocompatibility, can be specifically enriched at a lung lesion part and realize sustained release of sodium pyruvate, has remarkable targeting and sustained-release effects, and is suitable for preparing medicines for treating lung diseases.
Owner:JIANG SU PHARMAMAXCORP

Substituted pyrazolo piperidine carboxylic acids

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
Owner:BAYER AG

Method and system for extracting region of interest of lung disease pathology full-slice image

The invention discloses a method and a system for extracting a region of interest of a lung disease pathology full-slice image, relates to extraction of a region of interest, and aims to solve the technical problem of low accuracy of region of interest extraction in the prior art. Comprising the following steps: acquiring lung image data and calculating a semantic similarity score and a visual representation vector of each block; obtaining an optimal threshold according to the semantic similarity score, and screening out an index set; clustering the visual representation vectors of the blocks in the index set, and selecting the block with the highest semantic similarity score in each cluster as a representative block to obtain the index set; and based on the index set, extracting a feature matrix of each representative block, and backtracking to a space coordinate position of each representative block in the corresponding lung image data through an index to obtain a region of interest. Self-adaptive threshold filtering and recognition are carried out according to the semantic similarity score, and heterogeneity distribution of different wettability characteristics in the slice is reserved in the selected region of interest.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV +1